Sirtris Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference January 7, 2008

  
    
  
  
    
      Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical 
      company focused on discovering and developing small molecule drugs to 
      treat diseases of aging such as Type 2 Diabetes, announced today that it 
      will be presenting at the 26th Annual JPMorgan 
      Healthcare Conference on Monday January 7, 2008 at 1:30 pm PST in San 
      Francisco. Sirtris will discuss the Company’s 
      strategy for discovering and developing first-in-class therapeutics that 
      modulate sirtuins, a recently discovered class of enzymes that control 
      the aging process, as well as the Company’s 
      clinical progress. The presentation will be webcast live and can be 
      accessed on the Sirtris website, www.sirtrispharma.com, 
      in the investor relations section. A replay will be available 
      approximately twenty-four hours after the presentation and will be 
      archived on the Company’s website for two 
      weeks.
    
    
      About Sirtris Pharmaceuticals
    
    
      Sirtris Pharmaceuticals is a biopharmaceutical company focused on 
      discovering and developing proprietary, orally available, small molecule 
      drugs with the potential to treat diseases associated with aging, 
      including metabolic diseases such as Type 2 Diabetes. Our drug 
      candidates are designed to mimic certain beneficial health effects of 
      calorie restriction, without requiring a change in eating habits, by 
      activation of sirtuins, a recently discovered class of enzymes that 
      control the aging process. The company's headquarters are in Cambridge, 
      Massachusetts.
    
    
      This press release contains forward-looking statements within the 
      meaning of the Private Securities Litigation Reform Act of 1995. Such 
      statements include, but are not limited to, the potential therapeutic 
      effects of SIRT1 activators for diseases of aging, the progress and 
      results of pre-clinical and clinical studies of SIRT1 activators, 
      development of first-in-class therapeutics that modulate sirtuins, and 
      the potential of sirtuin modulators to receive regulatory approval. 
      These forward-looking statements about future expectations, plans and 
      prospects of Sirtris Pharmaceuticals involve significant risks, 
      uncertainties and assumptions, including risks related to the lack of 
      results that would provide a basis for predicting whether any of the 
      Company’s product candidates will be safe or 
      effective, or receive regulatory approval, the possibility that results 
      of pre-clinical studies are not necessarily predictive of clinical trial 
      results, the Company's potential inability to initiate and complete 
      pre-clinical studies and clinical trials for its product candidates, the 
      fact that none of the Company's product candidates has received 
      regulatory approvals, the potential inability of the Company to gain 
      market acceptance of the Company's product candidates, and those other 
      risks factors that can be found in the Company's filings with the 
      Securities and Exchange Commission. Actual results may differ materially 
      from those Sirtris Pharmaceuticals contemplated by these forward-looking 
      statements. Sirtris Pharmaceuticals does not undertake to update any of 
      these forward-looking statements to reflect a change in its views or 
      events or circumstances that occur after the date of this release.